275 related articles for article (PubMed ID: 27565923)
1. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B
Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Palmieri G; Merola G; Federico P; Petillo L; Marino M; Lalle M; Milella M; Ceribelli A; Montella L; Merola C; Del Prete S; Bergaglio M; De Placido S; Di Lorenzo G
Ann Oncol; 2010 Jun; 21(6):1168-1172. PubMed ID: 19880439
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
Liang Y; Padda SK; Riess JW; West RB; Neal JW; Wakelee HA
Lung Cancer; 2015 Jan; 87(1):34-8. PubMed ID: 25443273
[TBL] [Abstract][Full Text] [Related]
7. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma.
Perret A; Dômont J; Chamseddine AN; Dumont SN; Verret B; Briand S; Court C; Lazure T; Adam J; Ngo C; Even C; Levy A; Bayle A; Lucibello F; Haddag-Miliani L; Faron M; Honoré C; Le Cesne A; Mir O
Cancer Med; 2021 Jan; 10(1):230-236. PubMed ID: 33236839
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
Wang Y; Nie J; Dai L; Hu W; Chen X; Han J; Ma X; Tian G; Han S; Long J; Zhang Z; Fang J
Thorac Cancer; 2019 Jan; 10(1):17-23. PubMed ID: 30411854
[TBL] [Abstract][Full Text] [Related]
10. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.
Palmieri G; Buonerba C; Ottaviano M; Federico P; Calabrese F; Von Arx C; De Maio AP; Marino M; Lalle M; Montella L; Merola C; Milella M; Bergaglio M; Di Lorenzo G; Damiano V
Future Oncol; 2014 Nov; 10(14):2141-7. PubMed ID: 25471029
[TBL] [Abstract][Full Text] [Related]
12. A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.
Park S; Ahn MJ; Ahn JS; Sun JM; Shim YM; Kim J; Choi YS; Kim K; Shin S; Ahn Y; Kwon OJ; Kim H; Lee SJ; Chang WJ; Park K
J Thorac Oncol; 2013 Jul; 8(7):959-66. PubMed ID: 23722169
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients.
Valabrega G; Berrino G; Milani A; Aglietta M; Montemurro F
Breast J; 2015; 21(3):241-5. PubMed ID: 25772707
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
Jung HA; Kim M; Kim HS; Kim JH; Choi YH; Cho J; Park JH; Park KU; Ku BM; Park S; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2023 Feb; 18(2):223-231. PubMed ID: 36307042
[TBL] [Abstract][Full Text] [Related]
15. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Ali AS; Grönberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Österlund P; Welin S; Grønbæk H; Knigge U; Sorbye H; Janson ET
Med Oncol; 2018 Mar; 35(4):47. PubMed ID: 29511910
[TBL] [Abstract][Full Text] [Related]
16. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.
Giannone G; Milani A; Ghisoni E; Genta S; Mittica G; Montemurro F; Valabrega G
Breast; 2018 Apr; 38():160-164. PubMed ID: 29413403
[TBL] [Abstract][Full Text] [Related]
17. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Rajan A; Carter CA; Berman A; Cao L; Kelly RJ; Thomas A; Khozin S; Chavez AL; Bergagnini I; Scepura B; Szabo E; Lee MJ; Trepel JB; Browne SK; Rosen LB; Yu Y; Steinberg SM; Chen HX; Riely GJ; Giaccone G
Lancet Oncol; 2014 Feb; 15(2):191-200. PubMed ID: 24439931
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
[TBL] [Abstract][Full Text] [Related]
19. Oral etoposide for refractory or recurrent epithelial ovarian cancer.
Thavaramara T; Tangjitgamol S; Manusirivithaya S; Leelahakorn S
J Med Assoc Thai; 2009 Nov; 92(11):1397-405. PubMed ID: 19938729
[TBL] [Abstract][Full Text] [Related]
20. Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience.
Yellin A; Simansky DA; Ben-Avi R; Perelman M; Zeitlin N; Refaely Y; Ben-Nun A
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):83-7; discussion 87-9. PubMed ID: 23111024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
